Please provide your email address to receive an email when new articles are posted on . Phase 1 pharmacokinetics results showed comparability between SB17 and ustekinumab. Phase 3 results of SB17 will ...
Partners STADA and Alvotech today announced that the European Commission issued a marketing authorization for Uzpruvo® (AVT04), a biosimilar candidate to Stelara® (ustekinumab). The centralized ...
Johnson & Johnson’s second quarter earnings, released on Tuesday, largely beat analysts’ expectations, thanks in part to growth in autoimmune drugs, particularly by the Crohn’s disease medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback